- The FDA approved Roche Holding AG (OTC:RHHBY) unit Genentech’s Lunsumio (mosunetuzumab-axgb) for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
- This indication is approved under accelerated approval based on response rate, making Lunsumio the first CD20xCD3 bispecific to be authorized for this form of non-Hodgkin lymphoma (NHL).
- Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Roche is already working on a follow-up to Lunsumio with a subcutaneous formulation.
- Biogen Inc (NASDAQ:BIIB) exercised an option on the development of Lunsumio, paying Genentech a $30-million fee as part of a long-standing collaboration on antibodies targeting CD20.
- Under the agreed terms, Biogen will share in the operating profits and losses of the drug in the U.S. in the low- to mid-30% range.
- The FDA approval is based on positive results from the Phase II GO29781 study of Lunsumio in people with heavily pre-treated FL, including those at high risk of disease progression or whose disease was refractory to prior therapies.
- Results from the study showed high and durable response rates. An objective response was seen in 80% (72/90) of patients treated with Lunsumio, with a majority maintaining responses for at least 18 months (57%).
- Price Action: RHHBY shares are up 0.06% at $39.54 on the last check Friday.
Triple Flag Precious Metals Q1 Adj. EPS $012 Vs $0.08 YoY; Revenue $57.5M Vs $50.3M YoY
Q1 2024 Financial Highlights Q1 2024Q1 2023 Revenue$57.5 million$50.3 millionGold Equivalent Ounces ("GEOs")127,79426,599Net Earnings (per share)$17.4 million ($0.09)$16.5 million ($0.09)Adjusted
